排序方式： 共有7条查询结果，搜索用时 15 毫秒
1
1.
Rafiye Ciftciler Haluk Demiroglu Yahya Buyukasık Elifcan Aladag Salih Aksu Ibrahim C. Haznedaroglu Nilgun Sayınalp Osman Ozcebe Umit Yavuz Malkan Hakan Goker 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(3):177-182
Background
Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML.Patients and Methods
We retrospectively analyzed the clinical outcome of 91 patients who were diagnosed with treatment-refractory AML at Hacettepe University Hospital between January 2002 and June 2018. Patients' disease status included refractory AML, defined as failure to respond to standard induction chemotherapy and relapse within 6 months after first complete remission.Results
The median follow-up was 12 months (range, 0.5-184 months) for the entire group. Kaplan-Meier estimates of the 3-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 67% and 12%, respectively. Additionally, the Kaplan-Meier estimates of 5-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 44% and 4%, respectively (P < .001). Complete remission was obtained in 25 patients (83.3%) who underwent allo-HSCT; however, the disease of only 3 patients (3.8%) exhibited complete response after salvage chemotherapy.Conclusion
Allo-HSCT is still the best-known treatment option with curative potential in patients with treatment-refractory AML. Therefore, all efforts should be made in an attempt to find a suitable matched donor in order to perform allo-HSCT. 相似文献2.
Abay Rafiye Nur Katipoğlu Zeynep 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(12):3903-3908
Graefe's Archive for Clinical and Experimental Ophthalmology - Pseudoexfoliation (PEX) syndrome is an age-related disease characterized by the accumulation of extracellular material in many... 相似文献
3.
4.
Serap Uysal Yavuz Renda Meral Topçu Gülşen Erdem Rafiye Karacan 《Child's nervous system》1993,9(2):88-92
In this study the maturation of the central nervous system of full-term and premature infants were investigated electrophysiologically. The subjects were 16 full-term and 15 premature infants. Neurologic examination, psychometric tests, and measurement of evoked potentials were carried out periodically in babies who had no birth trauma, metabolic disorder, or intrauterine infection. Neurophysiologic comparison of the results was evaluated. As the babies grew older, I-V interpeak latency became shorter according to the results of brainstem auditory evoked potentials; N1-P1 amplitude became higher and P1 latency shorter according to the results of visual evoked potentials. Central nervous system maturation of full-term babies and prematures appear to be alike at 6 months of age. 相似文献
5.
Long-Term Prognosis After Neonatal Tetanus 总被引：1，自引：0，他引：1
Twenty-four Turkish children who had had neonatal tetanus were evaluated by means of physical and neurological examinations and psychometric tests at four to 15 years of age. Enuresis, mental retardation and growth retardation were frequent findings. The prevention of neonatal tetanus is important not only because of the high mortality rate but also because of its sequelae. 相似文献
6.
Rafiye Ciftciler Haluk Demiroglu Yahya Buyukasık Mufide Okay Salih Aksu Nilgun Sayınalp Umit Yavuz Malkan Ibrahim Celalettin Haznedaroglu Osman Ozcebe Hakan Goker 《Transfusion and apheresis science》2018,57(6):752-755
Background and Aim
This is a retrospective study aiming to investigate the effect of the number of high dose cytarabine-based chemotherapy (HiDAC) courses in patients with acute myeloid leukemia before allogenic stem cell transplantation (ASCT).Materials and Methods
A total of 110 patients with acute myeloid leukemia who received ASCT between 2001 and 2018 were included in the study.Results
Of the 110 patients, 25 (23%) patients received one course of HiDAC, 42 (38%) patients received two courses of HiDAC, 34 (31%) patients received three courses of HiDAC and 9 (8%) patients received four courses of HiDAC. Median follow-up for survivors was 71 months (range 4–186) for all patients. The 3-year overall survival for patients who received one course of HiDAC and patients who received more than one course of HiDAC were 49% and 70%, respectively (p?=?0.29). The 3-year disease free survival (DFS) for patients who received one course of HiDAC and patients who received more than one course of HiDAC were 38% and 66%, respectively (p?=?0.05). There was no statistically significant difference in OS between patients who received one or more than one consolidation chemotherapy. But there was nearly a statistically significant difference between patients who received one or more than one consolidation chemotherapy in DFS.Conclusion
In conclusion, the administration of more than one consolidation chemotherapy may provide longer DFS, however the number of consolidation chemotherapy is not associated with statistically significant differences in overall outcomes. 相似文献7.
Rafiye Ciftciler Ibrahim C. Haznedaroglu Osman Ozcebe Salih Aksu Nilgun Sayınalp Hakan Goker 《Immunopharmacology and immunotoxicology》2020,42(1):17-21
AbstractBackground and Aim: Recently, acute promyelocytic leukemia (APL) has shifted from the most hazardous to the best curable type of acute myeloid leukemia. Anthracyclines, all-trans retinoic acid (ATRA) and arsenic derivatives are the most important developments for the treatment of APL. ATRA promotes the terminal differentiation of malignant promyelocytes to mature neutrophils. We aimed to compare platelet and neutrophil recovery time after induction chemotherapy in patients with acute myeloid leukemia (AML) and APL.Materials and Methods: Two hundred and fifteen patients with AML and APL, who were diagnosed and treated in our tertiary care center between the years of 2001 and 2018 were evaluated.Results: One hundred and eighty one AML patients (84.2%) and 34 (15.8%) APL patients were included in this study. The time between neutrophil nadir after induction chemotherapy and neutrophil recovery was longer in APL patients than in AML patients [30.5 (4–52) vs. 20 (5–58), p?<?0.001]. The time between platelet nadir after induction chemotherapy and platelet recovery was longer in APL patients than in AML patients [21.5 (4–42) vs. 17 (4–45), p?=?0.02].Conclusion: Neutrophil and platelet recovery times were longer in APL patients than in AML patients in our present study. In 60?days, mortality rate was higher in APL patients than AML patients. Non-relapse mortality (NRM) rate was similar between two groups. There was a significant difference between two groups in terms of NRM causes. Platelet and neutrophil recovery time is very important because infection is the most important cause of NRM. 相似文献
1